Buy & Sell Prudential PLC (PUK) – Prudential PLC Price Today
Aura AI Summary
Key Stats
- $36.08BMarket Cap
- FinancialsSector
- -11.12%3M Drawdown
- $37.52BEnterprise Value
- 1.85%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 120 daysTypical Hold Time
Prudential PLC (PUK) is currently valued at a market capitalization of $36.08B, with an enterprise value of $37.52B. Over the past 52 weeks, Prudential PLC has traded between a low of $23.06 and a high of $33.61, highlighting its annual price range. Over the past three months, Prudential PLC has recorded a drawdown of -11.12%, reflecting recent price volatility. Prudential PLC offers a dividend yield of 1.85%, with the most recent dividend of $0.38 paid on 27 Mar 26. On average, investors hold Prudential PLC for approximately 120 days, indicating typical investor behavior on the platform.
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Most Recent News
Sphere 3D shares jump 28% after merger with Cathedra Bitcoin closes
Sphere 3D Corp. shares rose 28.11% in after-hours trading following the completion of its merger with Canadian digital infrastructure firm Cathedra Bitcoin Inc. The merger makes Cathedra a wholly-owned subsidiary of Sphere 3D, which retains its NASDA...

Above Food Ingredients stock plunges 36% after Nasdaq announces delisting over filing failures
Above Food Ingredients Inc. shares dropped nearly 36% in after-hours trading following Nasdaq's decision to delist the company's stock due to its failure to file audited financial statements and the required Annual Report on Form 20-F by the deadline...

Fulcrum Therapeutics shares plunge 49.7% after halting sickle cell drug development.
Fulcrum Therapeutics' stock dropped nearly 50% in after-hours trading after the company announced it is discontinuing its lead experimental drug, pociredir, for sickle cell disease. The decision follows FDA concerns about cancer risks linked to the d...
